Dear [ELECTED OFFICIAL],
As a constituent and an advocate with the Society for Immunotherapy of Cancer (SITC), I am writing to express concern regarding the Office of Management and Budget's (OMB) proposed changes to the regulations governing Federal Financial Assistance.
For decades, federal research funding has been awarded through a rigorous peer review process that relies on independent scientific experts to evaluate research proposals based on merit, innovation, feasibility, and potential impact. This system has helped make the United States the global leader in biomedical research and has contributed to countless medical advances that have improved and saved lives.
The proposed rule includes changes that could increase the role of political appointees in funding decisions and expand agencies' authority to suspend or terminate grants based on shifting priorities. In particular, proposed changes to Section 200.340 (Termination and Suspension) could create uncertainty for researchers and institutions that depend on stable, long-term funding to conduct scientific research.
Cancer research often requires years of sustained investment before discoveries can be translated into new treatments for patients. The current peer review system ensures that funding decisions are guided by scientific expertise and evidence, helping direct taxpayer dollars toward the most promising research opportunities. Moving away from this merit-based approach risks undermining the scientific rigor that has driven decades of progress against cancer and other serious diseases.
Federal investments in biomedical research have helped reduce cancer mortality, improve patient outcomes, strengthen the research workforce, and support local economies across the country. Continued success depends on maintaining a funding system that prioritizes scientific excellence and protects the integrity of the peer review process.
I respectfully urge you to exercise congressional oversight of these proposed regulatory changes and to support policies that preserve the central role of independent scientific peer review in federal research funding decisions. Congress has long recognized that the most effective way to advance medical innovation is to ensure that funding decisions are driven by scientific merit and potential patient benefit.
Patients, researchers, and institutions in our community depend on a strong and stable biomedical research enterprise. Thank you for your attention to this important issue and for your continued support of medical research.
Sincerely,
[Your Name]
[Your Title]
[Your Institution]
[City, State]